Welcome to the inaugural issue of Advances in Hematologic Malignancies, the new Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) eNewsletter for providers across the country and around the world who hold an interest in the field.
We have created this publication to keep you informed about exciting developments in our Center for Hematologic Oncology. At any given time, our center has more than 100 clinical trials open and recruiting patients. In addition, our more than 30 faculty members with disease-specific expertise are happy to discuss a challenging case with you or see a patient in consultation.
To keep you up to date on the most timely and relevant topics in hematologic oncology, we'll also bring you stories about ongoing clinical trials, particularly interesting and/or difficult cases, innovative laboratory-based research, and special features of our clinical practice here in Boston.
The focus of our first edition is the DF/BWCC Adult Lymphoma Program, which reflects a legacy of lymphoma research that began with the work of George Canellos, MD. Dr. Canellos first began explorations of combination chemotherapy in Hodgkin disease and other hematologic neoplasms in the 1970s. He shares his reflections on progress made in the ensuing decades in this publication.
Future issues of Advances in Hematologic Malignancies will feature, on a rotating basis, resources, news, and breakthroughs from the other five programs in our Center for Hematologic Oncology:
On behalf of our team here at DF/BWCC, we hope you find Advances in Hematologic Malignancies an informative and enjoyable read. Please don’t hesitate to contact us at DF_BWCCHemMaligNews@dfci.harvard.edu with your feedback and questions.
— David P. Steensma, MD, Oncologist in the DF/BWCC Adult Leukemia Program— Robert J. Soiffer, MD, Chief of the DF/BWCC Division of Hematologic Malignancies and Co-Chief of the DF/BWCC Adult Bone Marrow/Stem Cell Transplantation Program
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: